glp-1 gip vs tirzepatide Effects of tirzepatide, a dual and receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats Tirzepatide (LY3298176) is a Dual

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been pivotal for obesity treatment, achieving 1525 % weight loss over 1224 months, but questions remain about the potential influence of concomitant losses in muscle mass

Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring

In a phase 2 study, amycretin showed a mean weight reduction of up to 24.3%, which is comparable to or even greater than the weight loss seen with tirzepatide and similar to the results for retatrutide

In addition, activating GLP-1R reduced Iba-1, IL-1 and TNF- release and inhibited TNC microglial number and morphological changes (process retraction) following nitroglycerin administration